• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulation in COVID-19: not strong for too long?

作者信息

Tacquard Charles, Mansour Alexandre, Godon Alexandre, Gruel Yves, Susen Sophie, Godier Anne, Albaladejo Pierre

机构信息

Department of Anaesthesia and Intensive Care, Hôpitaux Universitaires de Strasbourg, 1, Place de l'Hôpital, 67091 Strasbourg Cedex, France.

Department of Anaesthesiology Critical Care Medicine and Perioperative Medicine, CHU de Rennes, Rennes, France.

出版信息

Anaesth Crit Care Pain Med. 2021 Apr;40(2):100857. doi: 10.1016/j.accpm.2021.100857. Epub 2021 Mar 30.

DOI:10.1016/j.accpm.2021.100857
PMID:33798761
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8008784/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a97/8008784/ab5bb05d7535/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a97/8008784/ab5bb05d7535/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a97/8008784/ab5bb05d7535/gr1_lrg.jpg

相似文献

1
Anticoagulation in COVID-19: not strong for too long?新冠疫情中的抗凝治疗：抗凝力度不宜过大且时间不宜过长？
Anaesth Crit Care Pain Med. 2021 Apr;40(2):100857. doi: 10.1016/j.accpm.2021.100857. Epub 2021 Mar 30.
2
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.COVID-19 重症监护患者中中剂量与标准剂量预防抗凝对血栓事件、体外膜肺氧合治疗或死亡率的影响：INSPIRATION 随机临床试验。
JAMA. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152.
3
Anticoagulation Management in Severe Coronavirus Disease 2019 Patients on Extracorporeal Membrane Oxygenation.严重 COVID-19 患者体外膜肺氧合抗凝管理。
J Cardiothorac Vasc Anesth. 2021 Feb;35(2):389-397. doi: 10.1053/j.jvca.2020.08.067. Epub 2020 Sep 4.
4
Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.COVID-19 重症监护病房患者中中剂量与标准剂量预防性抗凝治疗的比较：INSPIRATION 随机试验 90 天结果。
Thromb Haemost. 2022 Jan;122(1):131-141. doi: 10.1055/a-1485-2372. Epub 2021 Jun 6.
5
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.COVID-19 重症患者中中剂量与标准剂量预防性抗凝和他汀类药物治疗与安慰剂对照的研究：INSPIRATION/INSPIRATION-S 研究的原理和设计。
Thromb Res. 2020 Dec;196:382-394. doi: 10.1016/j.thromres.2020.09.027. Epub 2020 Sep 24.
6
Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review.体外膜肺氧合（ECMO）中无抗凝治疗的血栓形成和出血：系统评价。
ASAIO J. 2021 Mar 1;67(3):290-296. doi: 10.1097/MAT.0000000000001230.
7
Anticoagulation Practices during Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure. A Systematic Review.用于呼吸衰竭的静脉-静脉体外膜肺氧合期间的抗凝实践。一项系统评价。
Ann Am Thorac Soc. 2016 Dec;13(12):2242-2250. doi: 10.1513/AnnalsATS.201605-364SR.
8
Management of anticoagulation and hemostasis for pediatric extracorporeal membrane oxygenation.小儿体外膜肺氧合的抗凝与止血管理
Clin Lab Med. 2014 Sep;34(3):655-73. doi: 10.1016/j.cll.2014.06.014. Epub 2014 Jul 24.
9
Major bleeding complications in critically ill patients with COVID-19 pneumonia.新冠肺炎重症肺炎患者的主要出血并发症。
J Thromb Thrombolysis. 2021 Jul;52(1):18-21. doi: 10.1007/s11239-021-02403-9. Epub 2021 Mar 1.
10
Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study.体外膜肺氧合支持下的重症 COVID-19 患者的出血和血栓事件：一项全国性队列研究。
Intensive Care Med. 2022 Aug;48(8):1039-1052. doi: 10.1007/s00134-022-06794-y. Epub 2022 Jul 13.

引用本文的文献

1
Vascular Consequences: A Case Report on Posterior Circulation Infarction as a Sequela of COVID-19.血管并发症：一例新冠后遗症导致后循环梗死的病例报告
Cureus. 2024 Jul 31;16(7):e65837. doi: 10.7759/cureus.65837. eCollection 2024 Jul.
2
A Delphi consensus on the management of anticoagulation in the COVID-19 pandemic: the MONACO study.关于2019冠状病毒病大流行期间抗凝管理的德尔菲共识：摩纳哥研究
Cardiovasc Diagn Ther. 2023 Oct 31;13(5):777-791. doi: 10.21037/cdt-23-76. Epub 2023 Oct 25.
3
Anticoagulation in COVID-19.新冠疫情中的抗凝治疗

本文引用的文献

1
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.COVID-19 重症监护患者中中剂量与标准剂量预防抗凝对血栓事件、体外膜肺氧合治疗或死亡率的影响：INSPIRATION 随机临床试验。
JAMA. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152.
2
Major bleeding complications in critically ill patients with COVID-19 pneumonia.新冠肺炎重症肺炎患者的主要出血并发症。
J Thromb Thrombolysis. 2021 Jul;52(1):18-21. doi: 10.1007/s11239-021-02403-9. Epub 2021 Mar 1.
3
Lancet. 2022 Jan 1;399(10319):5-7. doi: 10.1016/S0140-6736(21)02503-4. Epub 2021 Dec 15.
4
Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis.住院COVID-19患者凝血功能障碍的中度至治疗性抗凝与预防性抗凝：一项系统评价和荟萃分析。
Thromb J. 2021 Nov 24;19(1):91. doi: 10.1186/s12959-021-00343-1.
5
Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study.比较纤维蛋白单体和D-二聚体以预测COVID-19肺炎重症患者的血栓形成事件：一项回顾性研究。
Thromb Res. 2021 Sep;205:8-10. doi: 10.1016/j.thromres.2021.06.009. Epub 2021 Jun 19.
6
Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021): From the French working group on perioperative haemostasis (GIHP) and the French study group on thrombosis and haemostasis (GFHT), in collaboration with the French society of anaesthesia and intensive care (SFAR).2019冠状病毒病患者静脉血栓栓塞的预防及止血监测：更新建议（2021年4月）：来自法国围手术期止血工作组（GIHP）及法国血栓形成与止血研究组（GFHT），与法国麻醉与重症监护学会（SFAR）合作制定
Anaesth Crit Care Pain Med. 2021 Aug;40(4):100919. doi: 10.1016/j.accpm.2021.100919. Epub 2021 Jun 25.
Intracerebral Hemorrhage in COVID-19 Patients with Pulmonary Failure: A Propensity Score-Matched Registry Study.
新冠肺炎合并肺衰竭患者的脑出血：一项倾向评分匹配登记研究。
Neurocrit Care. 2021 Jun;34(3):739-747. doi: 10.1007/s12028-021-01202-7. Epub 2021 Feb 23.
4
Arterial Thrombotic Events in Adult Inpatients With COVID-19.COVID-19 成年住院患者的动脉血栓栓塞事件。
Mayo Clin Proc. 2021 Feb;96(2):295-303. doi: 10.1016/j.mayocp.2020.11.018. Epub 2020 Nov 27.
5
Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave.COVID-19 第二波和第一波住院患者的血栓并发症发生率和总生存率。
Thromb Res. 2021 Mar;199:143-148. doi: 10.1016/j.thromres.2020.12.019. Epub 2020 Dec 30.
6
Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study.重症 COVID-19 患者更高抗凝目标与血栓形成事件风险：双中心队列研究
Ann Intensive Care. 2021 Jan 25;11(1):14. doi: 10.1186/s13613-021-00809-5.
7
Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients.自发性髂腰肌血肿（IPHs）：住院 COVID-19 患者的一个警示。
Ann Med. 2021 Dec;53(1):295-301. doi: 10.1080/07853890.2021.1875498.
8
Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.COVID-19 肺炎危重症患者高剂量预防性抗凝的影响。
Chest. 2021 Jun;159(6):2417-2427. doi: 10.1016/j.chest.2021.01.017. Epub 2021 Jan 16.
9
Venous Thromboembolism and Major Bleeding in Patients With Coronavirus Disease 2019 (COVID-19): A Nationwide, Population-Based Cohort Study.新型冠状病毒病 2019（COVID-19）患者的静脉血栓栓塞症和大出血：一项全国范围内的基于人群的队列研究。
Clin Infect Dis. 2021 Dec 16;73(12):2283-2293. doi: 10.1093/cid/ciab003.
10
Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up.新冠病毒疾病（COVID-19）住院治疗后有症状且经影像学确诊的静脉血栓栓塞症的发生率，并进行90天随访。
Blood Adv. 2020 Dec 22;4(24):6230-6239. doi: 10.1182/bloodadvances.2020003349.